Ovid Therapeutics (OVID) Price to Book (2017 - 2026)

Ovid Therapeutics (OVID) has reported Price to Book for 10 consecutive years, with 2.37 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book rose 462.94% year-over-year to 2.37; the trailing twelve-month figure through Jun 2026 stood at 2.37 (up 462.94% YoY), and the FY2025 full-year result was 0.92, down 4.97% from the prior year.
• Price to Book improved to 2.37 in Q2 2026 per OVID's latest filing, from 1.52 in the prior quarter.
• Across five years, Price to Book topped out at 2.76 in Q1 2024 and bottomed at 0.37 in Q1 2025.
• Historically, Price to Book has averaged 1.46 across 5 years, with a median of 1.22 in 2022.
• The sharpest annual moves came in 2025 and 2026: Price to Book plunged 86.52% in 2025, then soared 462.94% in 2026.
• Over 5 years, Price to Book stood at 0.99 in 2022, then jumped by 161.65% to 2.59 in 2023, then sank by 62.67% to 0.97 in 2024, then retreated by 4.97% to 0.92 in 2025, then soared by 157.41% to 2.37 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 2.37, 1.52, and 0.92 for Q2 2026, Q1 2026, and Q4 2025 respectively.